Mavyret is a combination therapy that is commonly used to help with a condition characterized by periods of heightened symptoms: chronic hepatitis C virus (HCV) infection. The medicine is considered relevant for the treatment of all six major HCV genotypes (GT1, GT2, GT3, GT4, GT5, and GT6) in adults and children aged 3 years and older, with or without compensated cirrhosis.

This therapeutic support contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations linked to organ-specific functional stress. This approach supports the overall management of the viral burden and assists with maintaining functional stability in situations where functional stability becomes affected. When symptoms become temporarily overwhelming, Mavyret supports improved day-to-day comfort and helps address symptom clusters that create noticeable physiological strain. The support provided is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Symptoms related to systemic imbalance.

Regulatory References

1. European Medicines Agency (EMA) overview

Eligibility Map: Who can and cannot use Mavyret — Official Regulatory Information

Mavyret (glecaprevir/pibrentasvir) is indicated for use in adult and pediatric patients 3 years and older with chronic Hepatitis C Virus (HCV) genotypes 1 through 6 infection. This includes patients with no cirrhosis or compensated cirrhosis (Child-Pugh A).

Contraindicated Populations

Official regulatory documents classify the following groups as contraindicated (must not use the medicine):

• Patients with moderate or severe hepatic impairment (Child-Pugh B or C).
• Patients with any history of prior hepatic decompensation.
• Patients taking atazanavir or rifampin concurrently.

Restricted or Not Recommended Use

Use is restricted for individuals with prior treatment experience. The medicine is not indicated for patients previously treated with both an HCV NS5A inhibitor and an NS3/4A protease inhibitor.

Use is not recommended with concomitant medications such as carbamazepine, efavirenz-containing regimens, or St. John's wort due to the risk of reduced therapeutic effect. The safety and effectiveness in children less than 3 years of age have not been established. No dose adjustment is required for patients with any degree of renal impairment, including those on dialysis, making it an allowed population for use.

Interactions with other medicines and products

Мавирет (glecaprevir/pibrentasvir) can interact with many other prescription and non-prescription medicines, herbal products, and supplements. These interactions can affect the safety and effectiveness of Мавирет or the other medicine.

Contraindicated and Not Recommended Combinations

It is contraindicated (must not be taken) with the HIV medicine atazanavir and the antibiotic rifampin. Co-administration is not recommended with strong enzyme inducers like the anticonvulsants carbamazepine, phenytoin, and phenobarbital, or the herbal product St. John’s Wort, as this can reduce the level of Мавирет in the body and lead to treatment failure.

Other Significant Interactions

• Statins (e.g., atorvastatin, simvastatin): Мавирет can significantly increase the levels of certain statins, which may raise the risk of muscle problems. Atorvastatin and simvastatin use is generally not recommended; other statins may require a reduced dose.
• Ethinyl Estradiol-Containing Products: Use with combined oral contraceptives or other products containing ethinyl estradiol is generally not recommended due to the potential for elevated liver enzymes.
• Other Medicines: Dose adjustments or close monitoring are required for medicines like digoxin (a heart medicine), certain HIV antivirals (e.g., efavirenz, lopinavir/ritonavir), cyclosporine, and vitamin K antagonists (blood thinners like warfarin).
• Diabetes and Vitamin K Antagonists: Due to potential changes in liver function, patients taking diabetes medicines or vitamin K antagonists require frequent monitoring (blood glucose or INR, respectively) and possible dose adjustment of those co-administered drugs.

Direct Inhibition of Viral Replication Machinery

The mechanism of action for Мавирет (glecaprevir/pibrentasvir) is based on the simultaneous, synergistic targeting of two distinct viral proteins essential for the Hepatitis C Virus (HCV) life cycle. The medication targets two critical nonstructural proteins: glecaprevir acts as an NS3/4A protease inhibitor to block the cleavage of the large viral polyprotein into mature, functional components, while pibrentasvir acts as an NS5A inhibitor to directly interfere with viral RNA replication and the final virion assembly.

---

Mechanistic Synergy and Sustained Viral Suppression

This dual blockade achieves suppression of the synthesis and spread of infectious particles, resulting in the complete cessation of the viral replication process within infected liver cells. The simultaneous inhibition of two essential and non-overlapping processes creates a broad resistance profile across all major HCV genotypes. This coordinated action initiates a cascade that leads to the rapid and sustained reduction of HCV RNA in the bloodstream, contributing to the physiological state where HCV RNA is reduced to undetectable levels.

How to Use Mavyret: Administration Guidelines

Mavyret (glecaprevir and pibrentasvir) is administered exclusively via the oral route as a fixed-dose combination, with treatment defined by a strict daily schedule and finite duration.

---

Standard Dosing and Frequency

The standard adult dosing regimen involves taking three film-coated tablets once daily. This delivers the full dose of 300 mg of glecaprevir and 120 mg of pibrentasvir. The entire dose must be taken at the same time each day.

A critical instruction for proper use is that Mavyret must be taken with food to ensure adequate absorption of the active ingredients. Tablets should be swallowed whole without chewing, crushing, or breaking.

---

Treatment Duration and Adjustments

The total treatment duration is predetermined and typically ranges from 8 to 16 weeks. An 8-week course is standard for most treatment-naïve adult patients across all six major HCV genotypes (GT1–GT6) without cirrhosis or with compensated cirrhosis. Extended durations of 12 or 16 weeks may be prescribed based on prior treatment experience or specific clinical circumstances.

No dose adjustment is required for patients with any degree of renal impairment or for those with mild hepatic impairment (Child-Pugh A).

---

Specific Instructions

• Missed Dose: If less than 18 hours have passed since the scheduled time, the dose should be taken with food immediately. If more than 18 hours have passed, the missed dose must be skipped, and the patient should resume the daily schedule at the next regularly scheduled time.
• Pediatric Use: The product is approved for patients aged 3 years and older. Pediatric dosing utilizes oral pellets for smaller children, which must be mixed with a small amount of soft food and swallowed without chewing.

Research evidence / Overview of studies for Mavyret

The research evidence for Mavyret (glecaprevir/pibrentasvir) is primarily based on a large clinical trial program, which included multiple Phase 3 studies and integrated analyses. The main goal of this research was to observe the virologic response 12 weeks after the end of the treatment, an outcome known as Sustained Virologic Response 12 weeks post-treatment (SVR12), a defined study endpoint.

---

Evidence for Chronic Hepatitis C Across All Genotypes (Pangenotypic)

This section summarizes the evidence base derived from key Phase 3 clinical trials, including randomized controlled trials and integrated analyses, which was studied for virologic response across all six major Hepatitis C genotypes (GT 1–6) in patients who had not been previously treated (treatment-naïve).

The trials, such as the ENDURANCE and EXPEDITION programs, were conducted in a broad range of patients, including those without cirrhosis and those with early or compensated cirrhosis (Child-Pugh A). Integrated analyses combining the results from these studies suggest patterns where SVR12 was measured across all six genotypes. The large pool of data helps show what has been observed so far for the general chronic HCV population, and research also explored patterns observed across different groups, including older adults.

---

Evidence in Patients with Treatment Challenges

This part was evaluated in specific patient groups who faced greater medical complexities or who had failed prior HCV treatment. The evidence base for these patients often comes from dedicated single-arm, open-label Phase 3 trials.

Research for Patients with Chronic Kidney Disease (CKD)

Specific research, such as the EXPEDITION-4 study, was observed in a cohort of patients with severe chronic kidney disease (CKD) Stage 4 or 5, including individuals on dialysis. The research describes SVR12 measurements in the population with severe chronic kidney disease. Research in this specialized group was undertaken to measure the virologic outcome.

Research for Patients with Prior Treatment Failure

Studies explored the use of Mavyret in patients who had previously been treated with an earlier generation of Direct-Acting Antivirals (DAAs) and failed to achieve SVR12. The data describe SVR12 measurements following retreatment in these individuals; research findings varied, and the observations were distinct from those reported in treatment-naïve patients.

---

Long-Term Response and Study Durability

The primary outcome in all pivotal trials was measured at 12 weeks post-treatment (SVR12), which is the standard regulatory outcome for virologic clearance. Consequently, follow-up durations were limited to this short interval, and long-term effects are not fully established. SVR12 serves as the primary outcome measured for the absence of the virus, but research that was observed in the long term (many years) regarding the prevention of all related liver disease complications is still emerging.

Key Studies & References

1. Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with HCV Genotypes 1–6 and Compensated Cirrhosis
2. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C - Patients with Renal Impairment

Common questions about Мавирет (FAQ)

---

Q: Does Мавирет interact with common pain relievers?

Official regulatory documents do not list common non-prescription pain relievers, such as ibuprofen or acetaminophen, as medications that are contraindicated with Мавирет. However, the official prescribing information notes that certain over-the-counter pain medications may be discouraged for individuals with severe liver impairment, a condition relevant to Hepatitis C.

---

Q: Is Мавирет safe for people who have had a liver transplant?

Official information states that Мавирет is used in adult and pediatric patients who are liver or kidney transplant recipients. Specific treatment durations are described for this patient population in regulatory documents.

---

Q: Is Мавирет an interferon-free treatment?

Yes, the medicine is classified as an interferon-free treatment. It is a combination of two Direct-Acting Antiviral (DAA) agents that target the Hepatitis C virus directly, which is distinct from older therapies that may have included interferon.

---

Q: Is Мавирет treatment known to cause anxiety or mood changes?

Anxiety or mood changes are not listed among the most commonly reported adverse reactions (which include fatigue and headache) in the regulatory safety profile.

---

Q: What is the risk of having a serious interaction with Мавирет?

Official product information describes that serious interactions are possible with certain medicines. For example, Мавирет is contraindicated with drugs such as atazanavir and rifampin. The combination is not recommended with specific anticonvulsants or herbal products due to the risk of either reduced therapeutic effect or increased drug concentrations.

---

Q: Why does the packaging of Мавирет include a warning about certain conditions?

The packaging contains a serious regulatory warning (often called a Boxed Warning) primarily regarding the risk of Hepatitis B Virus (HBV) reactivation. This warning applies to patients who are co-infected with both HCV and HBV. Warnings also address the risk of liver failure in patients with pre-existing advanced liver disease.

---

Q: Does Мавирет cause weight change?

Weight change is not listed among the adverse reactions that were most commonly reported in the regulatory safety profile, which categorizes reactions by frequency.

---

Q: Is it possible to be allergic to Мавирет?

The official product information specifies that the medicine is contraindicated in patients with known hypersensitivity, or allergic reactions, to the active substances (glecaprevir/pibrentasvir) or any of the inactive ingredients.

---

Q: Are there different versions or strengths of Мавирет available?

The medicine is supplied in two different forms. It is available as film-coated tablets for adults and older adolescents, and as oral pellets for use in younger pediatric patients.

---

Q: Can Мавирет be taken by people with HIV/AIDS who also have Hepatitis C?

Official clinical studies include data for patients co-infected with both HCV and HIV-1 who have compensated liver disease. However, regulatory documents note that adjustments may be required depending on the concurrent HIV antiviral medications being used.

---

Q: What official guidance is available for people who are pregnant or breastfeeding regarding Мавирет?

Official guidance indicates that there are no adequate data from human studies on the use of Мавирет during pregnancy. For breastfeeding, it is unknown whether the components of the medicine are found in human milk.

---

Q: Do official documents mention hair loss as a side effect of Мавирет?

Hair loss is not listed among the adverse reactions that were most commonly reported in the regulatory safety profile.

Mavyret (glecaprevir and pibrentasvir) must be stored according to official regulatory specifications to maintain product integrity.

Storage Conditions

Requirement	Specific Instruction
Temperature	Store at or below 30 C (86 F). Do not freeze.
Protection	Keep in the original packaging to protect from moisture and light.
Container Rule	Tablets must remain in the original blister card and carton until use.

Disposal Instructions

Any unused or expired medicine must be disposed of safely. The primary method is utilizing a drug take-back program. If a program is unavailable, official guidelines permit disposal in household trash after mixing the tablets with an undesirable substance (such as used coffee grounds or cat litter) and sealing the mixture in a container. The medicine must be kept out of the reach and sight of children, and it must not be flushed down the toilet or placed in wastewater systems.